Cantrixil, page-4

needle defending the company on disclosure...could be a first.

Specific rules from the ASX......I dont see a problem, but everybody can research and make up their mind .



https://www.asx.com.au/documents/re...e_for_Reporting_by_Life_Science_Companies.pdf



Reporting results Reporting of results of clinical trials should be made regardless of whether the outcome is positive or negative, and should be clear and unambiguous, specifically addressing the endpoints announced at the commencement of the trial. There should be a clear statement regarding the implications of the trial results for the further development and potential sale of the product being tested. Companies should indicate whether a further clinical trial or trials is necessary or planned. In meeting these requirements for disclosure, companies need to keep in mind the concerns of regulatory agencies regarding interpretation of results before they have been subjected to regulatory review. For example, companies need to be aware of the need to be consistent with the US Food and Drug Administration (FDA) guidance for media releases. The Code recognises the importance of peer review in the validation process and acknowledges that in some circumstances disclosure of results before peer review (through publication in a medical journal, presentation at a scientific meeting or otherwise) may be premature.